+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating how community pharmacies in under-resourced areas of Western New York can help identify and address social needs by integrating Community Health Workers CHWs. This study uses a quasi-experimental, difference-in-difference design to compare outcomes between patients who receive social needs screenings and referrals and those who do not. The goal is to understand the effectiveness of this program within the healthcare system. Community pharmacies participating in the study will distribute social needs screening surveys to patients. Based on the survey results, patients identified with needs will be referred by pharmacist navigators to local community-based organizations for support. The study compares individuals matched within the healthcare system who either receive the screening and referral intervention or do not. Participants will be adults aged 18 and older who speak English and visit participating pharmacies enrolled in the Community Pharmacy Enhanced Services Network or associated with Tops Pharmacies within Erie County. Researchers will measure effectiveness outcomes and analyze costs over 12 months to assess the programs impact. Participation involves completing surveys and being referred as needed, with no masking or randomization involved.

Age: 18Years +All GendersPhase Not Applicable
5 locations
R

Actively Recruiting

Researchers are evaluating the effects of YB-101 on thyroid function in people with Graves Disease. This trial aims to assess how safe and well tolerated YB-101 is, as well as how it is distributed in the body. The study includes two parts a first blinded treatment period and a second double-blinded treatment period, where participants receive either YB-101 or a placebo. Participants receive YB-101 or placebo through subcutaneous injections over a 24-week period. Those in Part 1 will not be eligible to join Part 2. The study involves approximately 34 to 39 visits at the clinic over about 40 weeks, depending on whether participants are in Part 1 or Part 2. Throughout the study, participants will attend many clinic visits to monitor their health and response to the treatment. Researchers will track adverse events and measure thyroid hormone levels including free triiodothyronine, free thyroxine, and thyroid-stimulating hormone. The study will also observe whether participants can stop anti-thyroid drugs regardless of levothyroxine use. Safety, tolerability, and effects on thyroid function will be assessed until about Day 169 of treatment.

Age: 18Years +All GendersPhase 2
32 locations
R

Actively Recruiting

Researchers are evaluating the effect of olpasiran compared to a placebo on the risk of coronary heart disease death, heart attack, or urgent coronary revascularization in people at risk for a first major cardiovascular event who have elevated lipoproteina levels. This phase 3 study focuses on participants aged 50 to 105 years with multiple cardiovascular risk factors or evidence of atherosclerosis. Participants will be randomly assigned to receive either subcutaneous injections of olpasiran or a placebo. The study is designed as a double-blind, placebo-controlled trial, meaning neither participants nor researchers know who receives the active drug or placebo. The treatment period spans up to approximately 6.2 years, during which participants receive regular injections and monitoring. Throughout the study, participants will be assessed for the time until coronary heart disease death, myocardial infarction, or urgent coronary revascularization occurs. Additional measurements include changes in lipoproteina levels and monitoring of cardiovascular events, strokes, and safety through adverse event tracking. Participants will have regular evaluations over the treatment duration, ensuring close follow-up until study completion.

Age: 50Years - 105YearsAll GendersPhase 3
252 locations